Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Non Operating Income: 2012-2023

Historic Non Operating Income for RedHill Biopharma (RDHL) over the last 9 years, with Jun 2023 value amounting to $47.5 million.

  • RedHill Biopharma's Non Operating Income rose 558.85% to $47.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$8.9 million, marking a year-over-year increase of 72.05%. This contributed to the annual value of $6.3 million for FY2024, which is 43.77% down from last year.
  • Per RedHill Biopharma's latest filing, its Non Operating Income stood at $47.5 million for Q2 2023, which was up 324.43% from -$21.2 million recorded in Q1 2023.
  • RedHill Biopharma's Non Operating Income's 5-year high stood at $47.5 million during Q2 2023, with a 5-year trough of -$63.9 million in Q4 2022.
  • Moreover, its 3-year median value for Non Operating Income was $3.9 million (2021), whereas its average is -$3.2 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 46,522.22% in 2020, then tumbled by 739.07% in 2021.
  • Over the past 5 years, RedHill Biopharma's Non Operating Income (Quarterly) stood at -$73,000 in 2019, then surged by 6,432.88% to $4.6 million in 2020, then slumped by 739.07% to -$29.5 million in 2021, then slumped by 116.18% to -$63.9 million in 2022, then skyrocketed by 558.85% to $47.5 million in 2023.
  • Its last three reported values are $47.5 million in Q2 2023, -$21.2 million for Q1 2023, and -$63.9 million during Q4 2022.